Deep cholestatic jaundice as the predominant manifestation in autoimmune hepatitis.
Autoimmune hepatitis is a chronic liver disease of unknown etiology. The diagnosis is based on the exclusion of other liver diseases such as drug-induced liver disease, alcohol liver disease, viral liver diseases and so on, characterizing by elevation of transaminases, hypergammaglobulinemia, auto antibodies and the histological features of interface hepatitis and plasma cells infiltration. However, deep cholestatic jaundice as the initial presentation, with elevated serum transaminases one month later, is rare in autoimmune hepatitis. We described a case of type 1 autoimmune hepatitis with deep cholestatic jaundice and hyperbilirubinemia as the initial predominant manifestation. It demonstrated that the cholestasis can also occur as the initial predominant syndrome in autoimmune hepatitis and respond well to the treatment with the glycyrrhizin and ursodeoxycholic acid.
Wang
Shu-Bing
SB
Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Sun Yat-Sen University, No. 58 Zhongshan Road II, Guangzhou, China.
Wang
Jin-Hui
JH
Zheng
Ru-Hua
RH
Zhong
Bi-Hui
BH
Chen
Min-Hu
MH
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001707:Biopsy, Needle; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D003937:Diagnosis, Differential; D005260:Female; D019695:Glycyrrhizic Acid / Q000627:therapeutic use; D019693:Hepatitis, Autoimmune / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D041781:Jaundice, Obstructive / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D008111:Liver Function Tests; D008875:Middle Aged; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D002756:Cholagogues and Choleretics; D019695:Glycyrrhizic Acid; D014580:Ursodeoxycholic Acid